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In postnatal day 7 rats, a unilateral intrastriatal injection of 12.5 nmol of N-methyl-D-aspartate 
(NMDA) reproducibly injures the ipsilateral striatum, adjacent hippocampus and overlying cortex. The 
severity of injury can be quantified by comparing cerebral hemisphere weights in animals sacrificed 5 days 
after the injection. Co-injection of NMDA and the glycine receptor antagonists kynurenic acid (KYN) 
or 7-chlorokynurenic acid (7-CKA) reduced the severity of NMDA-induced damage in a dose-dependent 
fashion. One hundred nmol of KYN with 12.5 nmol of NMDA reduced average % damage from 
19.3 + 0.9% (n = 9) to 2.3 + 0.5% (n = 6), P < 0.001, ANOVA. Co-injection of 40 nmol of 7-CKA with 12.5 
nmol of NMDA (n=6) reduced average % damage from 17.1 +1.6% (n= 15) to 3.0___0.6%, P<0.001, 
ANOVA. Concurrent injection of 1000 nmol glycine with 5 nmol NMDA did not increase the extent of 
NMDA-induced damage. Our results demonstrate that glycine receptor antagonists attenuate NMDA- 
induced brain injury in vivo. 
The N-methyl-D-aspartate (NMDA) receptor/channel complex includes the 
NMDA-selective glutamate binding site, a cationic channel, and a strychnine-insensi- 
tive glycine receptor which is closely associated with the receptor/channel complex 
[l]. In vitro studies have demonstrated that glycine is required for NMDA receptor 
activation [12] and potentiates NMDA responses [3]. Kynurenic acid and 7-chloroky- 
nurenic acid (7-CKA) are competitive antagonists of strychnine-insensitive [3H]gly- 
cine binding [4, 5]. 
Intrastriatal injection of NMDA in postnatal day (PND) 7 rats produces reproduc- 
ible damage to the ipsilateral striatum, adjacent hippocampus, and the overlying cor- 
tex [8]. The severity of brain injury can be quantified by comparing the weights of 
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the injected and contralateral cerebral hemispheres in animals sacrificed 5 days later, 
on PND 12 [9, 10]. In this study, we examined the ability of glycine receptor agonists 
and antagonists to potentiate or attenuate NMDA-induced brain injury in the imma- 
ture brain. To ensure consistent drug delivery, all drugs were administered by direct 
intra-cerebral injection. 
Seven-day-old Sprague-Dawley albino rats were anesthetized with diethyi ether. 
Stereotaxic injections of NMDA in 0.5/A phosphate-buffered saline (PBS) were made 
in the right striatum of each rat pup (co-ordinates referenced to bregma: AP 2 mm, 
ML 2.5 mm, V 4 mm). In the first experiment, pups received 5 nmol NMDA, with 
or without co-injection of 1000 nmol glycine. The next group of experiments included 
equal numbers of pups that received 12.5 nmol NMDA with or without co-injection 
of kynurenic acid (4 doses, 12.5-100 nmol) or 7-CKA (4 doses, 2.5-40 nmol). After 
recovery from anesthesia, the pups were returned to the dam. Animals were sacrificed 
by decapitation on postnatal day 12, 5 days after lesioning. 
The severity of brain injury was quantified by deriving a % damage value, calcu- 
lated as the difference between the contralateral hemisphere (C) weight and the 
injected (/) hemisphere weight, divided by the contralateral hemisphere weight (% 
damage= C-I/C x 100). Previous studies indicate that in this experimental model, 
the % damage value is a consistent measure of the severity of neuronal injury and 
the efficacy of neuroprotective agents [9]. At doses of NMDA ranging from 5 to 25 
nmol, there is a direct linear correlation between % damage and progressive reduc- 
tions in both choline acetyltransferase activity and striatal cross-sectional area [10]. 
Data was expressed as average % damage_+S.E.M, in all groups. At 12.5 nmol 
NMDA (n = 24) produced an average % damage of 18.1 _+ 1.2%. Brain injury was also 
evaluated by histologic examination of Nissl-stained coronal brain sections. 
The doses of drug that reduced damage by 505 (protective dose 50, PDs0) were 
determined by the method of Litchfield and Wilcoxon [6]. Statistical comparisons 
were made by analysis of variance (ANOVA). 
To examine the issue of potentiation of NMDA-induced injury by glycine, we used 
the lowest dose of NMDA, 5 nmol, that elicited a reproducible lesion. Injection of 
1000 nmol of glycine with 5 nmol NMDA did not increase NMDA-induced brain 
injury when compared to controls which received 5 nmol NMDA alone. Average % 
damage for experimentals (n = 6) was 9.3 + i.2%, compared with 10.5 _+ 1.2% for con- 
trols (n = 6), P = N.S., by ANOVA. 
In contrast, co-injection of increasing doses of the glycine receptor antagonist 
kynurenic acid (KYN) with 12.5 nmol NMDA progressively reduced the extent of 
NMDA-induced brain injury. Four doses of KYN were evaluated: 12.5 nmol (n = 6), 
25 nmol (n=6), 50 nmol (n=8) and 100 nmol (n=5). At each dose, the extent of 
NMDA-induced brain injury was reduced, P<0.001, ANOVA (Fig. 1A); % damage 
in brains injected with 100 nmol KYN fell to 2.3_+0.5%. The PDs0 for KYN was 34.1 
nmol. In addition, histologic sections confirmed a marked reduction in injury to the 
ipsilateral striatum, hippocampus and cortex in animals injected with 100 nmol KYN 
and 12.5 nmol NMDA (Fig. 2B) when compared to controls injected with 12.5 nmol 
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Fig. 1. Dos~response curves showing average % damage vs dose of kynurenic (KYN) acid (A) and 
7-chlorokynurenic acid (7-CKA) (B) with concurrent administration of 12.5 nmol N-methyl-o-aspartate 
(NMDA). Postnatal day (PND) 7 rats received right intrastriatal injection of 12.5 nmol NMDA with 
KYN (dose range: O-100 nmol) or 7-CKA (dose range: 0.40 nmol). Animals were sacrificed on PND 12. 
% damage was calculated by comparison of the injected (/) and contralateral (C) hemisphere weights 
(C-I/Cx 100) for each group and expressed as mean+S.E.M. *P<0.001, compared with 12.5 nmol 
NMDA-injected controls, ANOVA, post-hoc t-test indicated significant differences at each dose: 
**P< 0.001, compared with 12.5 nmol NMDA-injected controls, ANOVA, post-hoc t-tests indicated sig- 
nificant differences at doses 10, 20 and 40 nmol 7-CKA. 
The neuroprotective effects of 7-CKA on NMDA-induced brain injury were simi- 
lar. Doses of 7-CKA including 2.5 nmol (n = 9), 10 nmol (n = 6), 20 nmol (n = 6) and 
40 nmol (n = 6) were co-injected with 12.5 nmol NMDA. The lowest dose tested, 2.5 
nmol 7-CKA, did not reduce injury. Doses of 10, 20, and 40 nmol 7-CKA progres- 
sively reduced the severity of NMDA-induced brain injury, P < 0.001, ANOVA (Fig. 
1B). The PDs0 of 7-CKA calculated from these data was 17.6 nmol. Higher doses 
of 7-CKA could not be tested because of limitations in solubility of the drug. Coronal 
sections of brains injected with 40 nmol 7-CKA and 12.5 nmol NMDA (Fig. 2C) 
demonstrated relative preservation of histologic integrity of the striatum, hippocam- 
pus and cortex as compared to controls injected with 12.5 nmol NMDA only (Fig. 
2A). 
KYN has mixed glutamate antagonist properties, inhibiting [3H]glycine binding in 
a competitive manner and also inhibiting [3H]glutamate binding to NMDA receptors 
[2]. However, 7-CKA has 70-80 times the specificity of kynurenic acid for the strych- 
nine-insensitive glycine site [4]. The increased efficacy (lower PDs0) observed of 
7-CKA over KYN may be attributable to increased specificity of 7-CKA at the gly- 
cine modulatory site. These results are consistent with a recent report [11] which 
demonstrated that 7-CKA blocked glutamate neurotoxicity in cell culture and that 
glycine could reverse its neuroprotective effects. 
These data demonstrate that glycine receptor antagonists can attenuate NMDA- 
induced neurotoxicity in vivo. The inability of exogenous glycine to potentiate 
NMDA-induced brain injury may be due to maximal receptor occupation by physio- 
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Fig. 2. Representative Nissl-stained coronal brain section (75 llm) from rat pups sacrificed at postnatal 
(PND) day 12. On PND 7, ether anesthetized rats received right intrastriatal injections of 12,5 nmol 
NMDA (A), 12.5 nmol NMDA and 100 nmol KYN (B), and 12.5 nmol NMDA and 40 nmol 7-CKA 
(C). The severity of injury is markedly reduced by both KYN acid and 7-CKA. 
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